Health Economics›Soft tissue sarcoma›Locally advanced or metastatic disease first-line therapy

Locally advanced or metastatic disease first-line therapy

Soft tissue sarcoma · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Docetaxel and Gemcitabine Variant #01	—	R 4 912	21d	~6.2 mo	—	~9	~R 44 207 PFS proxy · indirect	1
Doxorubicin monotherapy Variant #10	—	R 1 293	21d	5.4 mo	19.0 mo	8	R 10 346 PFS proxy	6
Doxorubicin and Olaratumab Variant #01 Partial	—	R 718	21d	—	20.4 mo	—	—	1

3 of 3 regimens shown